|
C16ORF80 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.51909986998578E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.76180000880322E-09 |
| Normal-vs-Stage2 |
1.97097999999896E-05 |
| Normal-vs-Stage3 |
4.11880529682662E-11 |
| Normal-vs-Stage4 |
1.06149533607436E-11 |
| Stage1-vs-Stage2 |
3.305000E-01 |
| Stage1-vs-Stage3 |
1.224160E-02 |
| Stage1-vs-Stage4 |
2.680700E-03 |
| Stage2-vs-Stage3 |
1.450410E-02 |
| Stage2-vs-Stage4 |
6.183400E-03 |
| Stage3-vs-Stage4 |
5.567400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.76920050726426E-10 |
| Normal-vs-AfricanAmerican |
7.5170999999985E-05 |
| Normal-vs-Asian |
2.07230000004444E-06 |
| Caucasian-vs-AfricanAmerican |
5.787800E-01 |
| Caucasian-vs-Asian |
8.636900E-03 |
| AfricanAmerican-vs-Asian |
3.017200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.81860132192946E-11 |
| Normal-vs-Female |
3.16939996469756E-09 |
| Male-vs-Female |
4.110200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.35119995589872E-09 |
| Normal-vs-Age(41-60Yrs) |
2.66569999407551E-09 |
| Normal-vs-Age(61-80Yrs) |
1.97389993239483E-10 |
| Normal-vs-Age(81-100Yrs) |
1.649380E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.648600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.495230E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.993800E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.557800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.563410E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.148200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.586360E-02 |
| Classical-VS-Follicular |
5.090500E-02 |
| Classical-VS-Other |
7.342600E-01 |
| Classical-VS-Normal |
1.98899996473045E-09 |
| Tall-VS-Follicular |
4.587500E-04 |
| Tall-VS-Other |
3.731800E-01 |
| Tall-VS-Normal |
2.19569917803142E-11 |
| Follicular-VS-Other |
3.987600E-01 |
| Follicular-VS-Normal |
3.43989999995742E-06 |
| Other-VS-Normal |
6.039000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.33669999910791E-09 |
| Normal-vs-N1 |
8.17323986268548E-12 |
| N0-vs-N1 |
7.497000E-03 |
|
|
